Document:

ex109

11415293v2  CITIZENS COMMUNITY BANCORP, INC.  LONG-TERM INCENTIVE PLAN AWARD AGREEMENT  Award Date: _______________________________  RS No. ________________  I. The Award and the Plan. As of the Award Date set forth above (the “Award Date”), Citizens Community Bancorp, Inc. (the “Company”) grants to ________________ (“you”) the award (the “Award”) stated in this Long-Term Incentive Plan Award Agreement (this “Agreement”). The Award consists of the following: (a) ____________ time-based restricted Shares of the Company (the “Time-Based Restricted Shares”), and (b) Share Units representing a commitment to issue you Shares of the Company upon achievement of the Performance Criteria, as defined in the Appendix (the “Performance- Based Restricted Shares”), all on the terms and conditions contained in this Agreement and the Citizens Community Bancorp, Inc. 2018 Equity Incentive Plan (the “Plan”). II. Terms of Time-Based and Performance-Based Restricted Share Grants. 2.1 Time-Based Restricted Shares. Until your Time-Based Restricted Shares vest,  you may not sell, assign, pledge or otherwise transfer such Shares (or any interest  in or right to such Shares), other than by will or the laws of descent and  distribution, and any such attempted transfer will be void (the “Restrictions”). The  Time-Based Restricted Shares vest, and the Restrictions will lapse, in accordance  with the following vesting schedule:  ________ of the Time-Based Restricted Shares shall vest on the  one-year anniversary of the Award Date;  ________ of the Time-Based Restricted Shares shall vest on the  two-year anniversary of the Award Date; and  ________ of the Time-Based Restricted Shares shall vest on the  three-year anniversary of the Award Date.  2.2 Performance-Based Restricted Shares.  The commitment to issue you Shares of  the Company upon achievement of the Performance Criteria with respect to the  Performance-Based Restricted Shares shall be based on a Target number of  Shares.  The Target number of Shares pursuant to this Award of Performance- Based Restricted Shares is __________ Shares.  The number of Shares actually  issued to you, if any, upon achievement of the Performance Criteria shall be as  provided in the Appendix.  Upon expiration of the Performance Period, the Compensation Committee (the  “Committee”) will determine in its sole discretion whether the Performance  Criteria has been met. To the extent the Performance Criteria has been met,  Shares of the Company will be deemed to be earned by you, and the applicable  number of Shares will be delivered to you within 30 days after the Committee  Exhibit 10.9 

 

11415293v2       2    makes such determination. The foregoing provisions of this Section 2.2  notwithstanding, upon the occurrence of a Change of Control, the Committee will  determine whether and to what extent the Performance Criteria has been attained  through the date of such Change of Control, and you will be deemed to have  earned the greater of (i) such number of Shares as would have been earned based  on the attainment of Target performance under the Performance Criteria or (ii)  such number of Shares as would be earned based on the actual Performance  Criteria attained as so determined by the Committee. You may not sell, assign,  pledge or otherwise transfer any rights to Performance-Based Restricted Shares  prior to the expiration of the Performance Period, or prior to the issuance of any  Shares earned during the Performance Period, other than by will or the laws of  descent and distribution.  2.3 Effect of Disability, Death or other Termination of Employment on Time- Based Restricted Shares. Your employment with the Company may be  terminated by your employer at any time for any reason (with or without advance  notice).  (a) Except as provided in (b) below, if your employment with the Company is  terminated before the Restrictions have lapsed, for any reason, you will  forfeit all unvested Time-Based Restricted Shares.  (b) If your employment with the Company is terminated by reason of your  death, or Disability, the Restrictions will lapse with respect to your Time- Based Restricted Shares upon the date of such termination of employment.  2.4 Effect of Disability, Death or other Termination of Employment on  Performance-Based Restricted Shares. Your employment with the Company  may be terminated by your employer at any time for any reason (with or without  advance notice).  (a) Except as provided in (b) below, if your employment with the Company is  terminated before the end of the Performance Period, for any reason, your  rights to all unearned Performance-Based Restricted Shares will be  forfeited.  (b) If your employment with the Company is terminated by reason of your  death or Disability, to the extent the Performance Criteria has been met as  of such date, you will be entitled to a pro-rated amount of Shares of the  Company. The pro-rated portion will equal a fraction of such earned  Shares, the numerator of which is the number of days during the  Performance Period you were employed through the date of termination of  employment and the denominator of which is 1,095. The Shares will be  delivered to you within 30 days after approval of the Performance Criteria.  2.5 Limitation of Rights Regarding Shares. Upon issuance of any Time-Based  Restricted Shares, you will have all of the rights of a shareholder with respect to  

 

11415293v2       3    such Shares, including that you will have the right to vote any unvested Time- Based Restricted Shares and you will have any right to any dividends paid on any  unvested Time-Based Restricted Shares. You will not have any rights in any  Performance Based Restricted Shares prior to the expiration of the Performance  Period, and prior to the issuance of any Shares earned during the Performance  Period.  2.6 Income Taxes. You are liable for any federal and state income or other taxes  applicable upon the lapse of the Restrictions on any Time-Based Restricted  Shares (or at any such earlier time, if any, that an election is made by you under  Section 83(b) of the Code, or any successor thereto), and your subsequent  disposition of any Time-Based Restricted Shares that have become vested, and  you acknowledge that you should consult with your own tax advisor regarding the  applicable tax consequences. Upon (a) the lapse of Restrictions on any Time- Based Restricted Shares or (b) the issuance of any earned Shares relating to  Performance-Based Restricted Shares, except as otherwise agreed, the Company  will withhold from such Shares a number of Shares having a Fair Market Value  equal to the amount of all applicable taxes required by the Company to be  withheld upon the lapse of the Restrictions on such Shares, or upon the issuance  of Shares earned relating to Performance-Based Restricted Shares.  III. Restrictive Covenants.  3.1 Basis for Restrictions. You acknowledge and agree that the Company’s business,  technical, and customer information is established and maintained at great  expense to the Company and is of significant value to the Company, and that by  virtue of employment with the Company, you will have information pertaining to,  unique and extensive exposure to, and personal contact with, the Company’s  business, technical and customer information which would enable you to compete  unfairly with the Company.  As a result, and in consideration of the Company’s  grant and your acceptance of the Award set forth herein, you acknowledge and  agree that the restrictions set forth in this Section III are necessary and  enforceable to protect the Company’s business.  3.2 Confidential Information.  For purposes of this Agreement, “Confidential  Information” means information disclosed to you or known by you as a result of  or as disclosed in the course of your employment with the Company which is not  generally known to the public pertaining to the Company’s business, including,  but not limited to, operations, contracts, customers, customer lists, proposals,  research and development, procedures and protocols, operating models, financial  information, pricing, price lists, marketing methods, strategic planning  information, information stored in or developed for use with Company’s  computer systems, insurance plans, risk management information, or marketing  programs, and third-party information that the Company may learn from its  customers or clients.  Confidential Information shall include any such information  developed or created by you if the information was developed or created by you  while executing your duties for the Company or if the information was developed  

 

11415293v2       4    or created by you based upon any Confidential Information that you learned by  virtue of your employment with the Company.  Confidential Information shall not  include any information that you can demonstrate is in the public domain by  means other than disclosure by you, but shall include non-public compilations,  combinations, or analyses of otherwise public information.  3.3 Non-Disclosure or Use of Confidential Information. For as long as you shall  remain employed by the Company, and after termination of employment with the  Company for any reason, you shall not directly or indirectly, under any  circumstances, communicate or disclose to any person, firm, association,  corporation, company or any other third party, or use for your own benefit or the  benefit of any person or entity other than the Company, any Confidential  Information, and you will keep secret and in strict confidence and hold inviolate  said Confidential Information.  You further agree not to disclose to others or use  at any time after the termination of your employment with the Company any  Confidential Information that constitutes and remains a trade secret under the  Wisconsin Trade Secrets Act, as amended (Section 134.90 Wis. Stats.), any  Confidential Information that the Company received from a third party and  continues to hold in confidence, and any Confidential Information that you are  otherwise prohibited by law from disclosing to others or using.  The prohibitions  of this paragraph do not apply to Confidential Information after it has become  generally known and/or in the public domain through no fault of yours.  The  prohibitions of this paragraph also do not prohibit use of your general skills and  knowledge acquired during and prior to your employment by the Company, as  long as such use does not involve the use or disclosure of Confidential  Information.  3.4 Defend Trade Secrets Act. You understand that if you breach the provisions of  Section 3.3 above, you may be liable to the Company under the Defend Trade  Secrets Act of 2016 (“DTSA”).  You further understand that by providing you  with the following notice, the Company may recover from you its attorney fees  and exemplary damages if it brings a successful claim against you under the  DTSA:  Under the federal Defend Trade Secrets Act of 2016, you shall not be  held criminally or civilly liable under any federal or state trade secret law for the  disclosure of a trade secret that is made:  (a)(i) in confidence to a federal, state, or  local governmental official, either directly or indirectly, or to an attorney and (ii)  solely for the purpose of reporting or investigating a suspected violation of law or  (b) in a complaint or other document filed in a lawsuit or other proceeding, if such  filing is made under seal.  Without limiting the foregoing, if you file a lawsuit for  retaliation by the Company for reporting a suspected violation of law, you may  disclose the trade secret to your attorney and use the trade secret information in  the court proceeding, if you (i) file any document containing the trade secret  under seal and (ii) do not disclose the trade secret, except pursuant to court order.  3.5 Non-Solicitation of Customers. During your employment, and for a period of  twelve (12) months following the termination of your employment with the  Company for any reason, you shall not, directly or indirectly canvas, contact,  

 

11415293v2       5    reply to, or solicit any “Active Customer” (as defined below) of the Company for  the purpose of selling, offering or providing products or services which are the  same as or substantially similar to the products or services provided by the  Company at any time during the “Reference Period” (as defined below).  “Active  Customer” shall mean any person or entity which, within the 12-month period  prior to the termination of your employment with the Company (the “Reference  Period”), received any products or services supplied by or on behalf of the  Company; provided, however, “Active Customer” shall be further limited to those  customers of the Company: (i) with whom you had material business contact as  an employee of the Company during the Reference Period; (ii) whose dealings  with the Company were coordinated or supervised, in whole or in part, by you  during the Reference Period; or (iii) about whom you obtained Special  Knowledge (as defined below) as a result of your position with the Company  during the Reference Period. “Special Knowledge” means Confidential  Information that is used, possessed or acquired by or developed for the Company  in the course of soliciting, selling to or servicing a customer, including, but not  limited to, existing or proposed bids, pricing and cost information, margins,  negotiation strategies, sales strategies and information generated for customer  engagements.  3.6 Non-Solicitation of Company Personnel. During your employment and for a  further period of twelve (12) months beginning on the termination of your  employment with the Company for any reason, you agree that you shall not,  directly or indirectly, solicit, encourage or induce any employee, consultant,  contractor, or other agent of the Company with whom you had substantial contact  during the Reference Period and who has knowledge of Confidential Information  to terminate a relationship (employment or otherwise), or breach any agreement  with the Company.  3.7 Severability and Blue Penciling. To the extent that any provision of this Section  III shall be determined to be invalid or unenforceable as written, the validity and  enforceability of the remainder of such provision and of this Agreement shall be  unaffected.  If, at the time of enforcement of the covenants contained in this  Section III (collectively, the “Restrictive Covenants”), a court shall hold that the  duration, scope or area restrictions stated are unreasonable under circumstances  then existing, you and the Company agree that the maximum duration, scope or  area reasonable under such circumstances shall be substituted for the stated  duration, scope or area and that the court shall be allowed to revise the Restrictive  Covenants to cover the maximum duration, scope and area permitted by law.  3.8 Reasonable and Necessary. You have had the opportunity to consult with your  own legal counsel regarding the Restrictive Covenants and agree that the  Restrictive Covenants are reasonable in terms of duration, scope and area  restrictions and are necessary to protect the goodwill of the Company’s businesses  and agree not to challenge the validity or enforceability of the Restrictive  Covenants.  You agree that the provisions of this Section III are an essential  inducement to the Company to enter into this Agreement and they are in addition  

 

11415293v2       6    to, rather than in lieu of, any similar or related covenants with the Company to  which you may be bound.  3.9 Remedies. If you breach, or threaten to commit a breach of any of the Restrictive  Covenants, the Company shall have the following rights and remedies, each of  which rights and remedies shall be independent of the others and severally  enforceable, and each of which is in addition to, and not in lieu of, any other  rights and remedies available to the Company at law or in equity:  (a) The right and remedy to immediately cancel, and you would thereby  forfeit, any unvested Time-Based Restricted Shares and any unearned  Performance-Based Restricted Shares awarded under this  Agreement; and  (b) The right and remedy to have the Restrictive Covenants specifically  enforced by any court of competent jurisdiction, it being agreed that any  breach or threatened breach of the Restrictive Covenants would cause  irreparable injury to the Company and that money damages would not  provide an adequate remedy to the Company; and  (c) The right and remedy to require you to account for and pay over to the  Company any profits, monies or other benefits derived or received by you  as the result of any transactions constituting a breach of the Restrictive  Covenants; and  (d) The right to payment from you of the Company’s costs and reasonable  attorney fees incurred in successfully enforcing the Restrictive Covenants.  3.10 Survival. Notwithstanding any termination of this Agreement or your  employment with the Company, whether or not any Time-Based Restricted  Shares awarded hereunder have in whole or in part vested at that time or whether  any Performance-Based Restricted Shares have been earned, you shall remain  bound by the provisions of Section III of this Agreement which specifically relate  to periods, activities or obligations upon or subsequent to the termination of your  employment.  IV. General Terms and Conditions.  4.1 Employment. This Agreement does not guarantee your continued employment  nor alter the right of the Company to terminate your employment at any time.   4.2 Terms of Plan. This Award is granted pursuant to the Plan and is subject to its  terms. The terms and provisions of the Plan as it may be amended from time to  time are hereby incorporated herein by reference. In the event of any conflict  between the provisions of this Agreement and the Plan, the provisions of the Plan  will govern. All determinations and interpretations made in the discretion of the  Committee shall be binding and conclusive upon you and your legal  representatives with regard to any question arising hereunder or under the Plan.  

 

11415293v2       7    By your acceptance of this Award, you acknowledge receipt of a copy of the Plan  and your agreement to the terms and conditions of the Plan and this Agreement.  4.3 Capitalized Terms.  Capitalized terms not defined in the body of this Agreement  are defined in the Plan. Except as otherwise stated, all references to “Sections” or  “Articles” refer to Sections or Articles of this Agreement.  4.4 Governing Law. This Agreement is governed by the laws of the State of  Wisconsin, without regard to the conflict of law provisions.  4.5 Certificates for Shares. The Company may issue stock certificates or evidence  your interest in any Shares by using a restricted book entry account with the  Company’s transfer agent. The Company shall hold any certificates for your  benefit until the Shares represented thereby become vested.  Any certificate(s) or  other document(s) delivered to you may bear a legend indicating restrictions on  transferability of the Shares pursuant to this Agreement and the Plan or any other  restrictions that the Committee may deem advisable.   4.6 Adjustments. If any change is made to the outstanding common stock or the  capital structure of the Company, the number and class of Shares covered by this  Agreement and the terms and conditions of this Agreement shall be appropriately  adjusted in any manner as contemplated by the Plan by the Committee, whose  determination shall be conclusive.  4.7 Amendment. The Committee may waive any conditions of or rights of the  Company or modify or amend the terms of this Agreement; provided, however,  that the Committee may not amend, alter, suspend, discontinue or terminate any  provision hereof which may adversely affect you without your (or your legal  representative’s) written consent.    4.8 Insider Trading Policy Acknowledgement.  You hereby acknowledge that you  have received, or have had access to, the Company’s Insider Trading Policy.  You  acknowledge, agree and understand that any purchase or sale of Shares, or any  attempted sale or transfer of the Shares, are subject to and governed by the  provisions of the Insider Trading Policy.  By executing this Agreement or  accepting this award, you agree to abide by and follow such the terms of the  Insider Trading Policy.  4.9 Entire Agreement. This Agreement, together with the Plan, constitute the entire  agreement relating to the subject matter hereof and supersede all previous and  contemporaneous communications, agreements and understandings between you,  on the one hand, and the Company or any of its affiliates, on the other hand.  4.10 Counterparts. This Agreement may be executed in counterparts, each of which  shall be deemed an original but all of which together will constitute one and the  same instrument. Counterpart signature pages to this Agreement transmitted by  facsimile transmission, by electronic mail in portable document format (.pdf), or  by any other electronic means intended to preserve the original graphic and  

 

11415293v2       8    pictorial appearance of a document, will have the same effect as physical delivery  of the paper document bearing an original signature.         

 

    IN WITNESS WHEREOF, the parties hereto have caused this Award Agreement to be  executed as of the date first above written.      CITIZENS COMMUNITY BANCORP, INC.        By: ________________________________    Name: ______________________________    Title: ________________________________      ACCEPTED:        By: ________________________________    Name: ______________________________    _________________________________  (Street Address)    _________________________________  (City, State and Zip Code)    

 

11415293v2  10  APPENDIX  PERFORMANCE-BASED RESTRICTED SHARES  1. Performance Criteria; Performance Period; Performance Shares Earned. The number of performance shares that may be earned under this Award is based on the attainment of the following performance criteria (the “Performance Criteria”): The performance of the Company, as determined by Return on Average Equity (ROAE), over  the period commencing on January 1, _____ and ending on December 31, ____(except as set  forth in the Agreement to which this Appendix is attached) (the “Performance Period”). The  number of performance shares that may be earned under this Award are as follows:  Performance Level Performance Achieved Number of Shares Earned  Below Threshold Less than 6.72% for the Performance Period 0 Shares  At Threshold _____% for the Performance Period 50% of Target Number of Shares  At Target _____% for the Performance Period 100% of Target Number of Shares  At Maximum _____% for the Performance Period 150% of Target Number of Shares  The number of performance shares earned will be interpolated on a linear basis for performance between  Threshold and Target and between Target and Maximum.   2. No Guaranteed Payout. The minimum number of shares which may be earned is zero and the maximum number of shares which may be earned is 150% of the Target number of Performance Shares. There is no minimum number of shares or other consideration that will be paid out, and no shares will be earned if the performance achieved is below threshold for the Performance Period. 2020 2022 6.72 8.40 10.08Exhibit 10.1

 

EXECUTION VERSION

 

COOPERATION AGREEMENT

 

This Cooperation Agreement,
dated as of March 7, 2021 (this “Agreement”), is by and between Berkshire Hills Bancorp, Inc., a Delaware corporation
(together with its Affiliates, the “Company”), and HoldCo Asset Management, LP, a Delaware limited partnership
(together with its Affiliates, “HoldCo” and, together with the Company, the “Parties” and
each individually a “Party”).

 

In consideration of
and reliance upon the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration,
the receipt and sufficiency of which is acknowledged, HoldCo and the Company agree as follows:

 

1.                 
Board Nominations and Related Matters.

 

(a)              
2021 Annual Meeting Nominations. The Board of Directors of the Company (the “Board”) shall take
the following actions in connection with the Company’s 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”),
in each case, in accordance with the Amended and Restated Certificate of Incorporation of the Company (the “Certificate”),
the Amended and Restated Bylaws of the Company (the “Bylaws”), and the Delaware General Corporation Law (the
 “DGCL”):

 

(i)                
nominate up to thirteen (13) candidates for election as directors of the Company, with terms expiring at the Company’s
2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”), which nominees will consist of:

 

A.               
Michael Zaitzeff (the “Investor Nominee”);

 

B.                
one (1) new, Qualified Director (as defined below) identified and selected by the Company, with the consent of HoldCo (not
to be unreasonably withheld, conditioned or delayed) (the “New Independent Director” and, together with the
Investor Nominee, the “New Directors”); and

 

C.                
members of the Company’s current Board as of the date of this Agreement;

 

(ii)             
recommend that the stockholders of the Company vote to elect each person included in the Company’s slate of director
nominees (including each New Director) as a director of the Company at the 2021 Annual Meeting; and

 

(iii)           
support the election of each New Director and, for the avoidance of doubt, any Replacement Investor Nominee (as defined
below) at the 2021 Annual Meeting in a manner no less rigorous or favorable than that in which the Company supports the other director
nominees of the Company with respect to the 2021 Annual Meeting.

 

(b)              
Withdrawal of HoldCo Nominations. Concurrently with and effective upon the execution of this Agreement, HoldCo shall
irrevocably withdraw its director nomination notice dated February 19, 2021, which notice shall be deemed null, void and without
effect.

 

     

     

    

 

(c)              
 Committee Membership. Effective upon their election to the Board, the Board shall take all such actions as are necessary
to appoint (i) the Investor Nominee to the Audit Committee and the Risk Management and Capital Committee of the Board, and
as a non-voting observer of the Corporate Governance/Nominating Committee of the Board; and (ii) the New Independent Director to
at least one standing committee of the Board to be determined by the Corporate Governance/Nominating Committee of the Board.

 

(d)              
No Compensation Arrangements. HoldCo agrees that it will not (i) pay any compensation to any New Director regarding
such person’s service on the Board or any committee thereof or (ii) have any agreement, arrangement or understanding,
written or oral, with any person other than the Investor Nominee regarding such person’s service on the Board or any committee
thereof (including pursuant to which such person will be compensated for his or her service as a director on, or nominee for election
to, the Board or any committee thereof).

 

(e)              
Replacement Investor Nominee. Subject to Section 1(f), if the Investor Nominee (or any Replacement Investor
Nominee (as defined below)) is unable or unwilling to serve as a director or director nominee, resigns as a director or director
nominee, is removed as a director or director nominee or ceases to be a director or director nominee for any other reason prior
to the 2022 Annual Meeting, HoldCo shall be permitted to select (subject to the Company’s prior written consent, not to be
unreasonably withheld, conditioned or delayed), and the Board shall take all actions as are necessary to appoint or nominate, as
applicable, a substitute director or director nominee (a “Replacement Investor Nominee”) for service as a director
of the Company for the remainder of the Cooperation Period; provided, that any Replacement Investor Nominee must be a Qualified
Director. Effective upon the appointment of a Replacement Investor Nominee to the Board, such Replacement Investor Nominee will
be considered the Investor Nominee for all purposes of this Agreement.

 

(f)               
Limitations on Director Appointment Rights. Notwithstanding anything in this Agreement to the contrary, the Company’s
obligations under this Section 1 shall terminate, and HoldCo shall have no nomination or other rights under this Section 1,
upon the earlier of such time as: (A) HoldCo ceases to beneficially own at least 2% of the current (as of the date of this Agreement)
outstanding shares of common stock, par value $0.01, of the Company (the “Company Common Stock”); (B) HoldCo
notifies the Company that the Investor Nominee (and, for the avoidance of doubt, any Replacement Investor Nominee) has determined
not to stand for election to the Board at the 2021 Annual Meeting; or (C) HoldCo or another Restricted Person breaches in
any material respect any of the terms of this Agreement (including, for the avoidance of doubt, Section 2); provided,
that the Company has provided HoldCo with written notice of such breach and, if such breach is capable of being cured, such breach
has not been cured within ten (10) days of such written notice. In the case of clauses (A) and (C), if the Investor Nominee is
on the Board at such time, then HoldCo shall cause the Investor Nominee promptly to, and Investor Nominee shall, tender written
notice to the Chair of the Board providing for his immediate resignation from the Board and any committee of the Board on which
he then sits.

 

(g)               New
Director Information. If the Board learns of any information that would constitute grounds for removal for cause from the
Board under applicable law, then the Board may withdraw such New Director’s nomination or request that such New
Director submit his or her resignation (if such New Director has already been elected to the Board in accordance with Section 1(a))
and, if such New Director is the Investor Nominee, a Replacement Investor Nominee shall be selected as provided in Section 1(e).
Any Replacement Investor Nominee will be required to, prior to such person’s nomination or appointment to the Board (as
applicable), provide information the Company reasonably requires, including in response to the Company’s D&O
questionnaire utilized with respect to its directors or otherwise required to be disclosed in a proxy statement or other
filing under applicable law, stock exchange rules or listing standards, in connection with assessing eligibility,
independence and other criteria applicable to directors and committee members or satisfying compliance and legal obligations,
and will consent to appropriate background and credit checks, in each case, consistent with the information and background
and credit checks required by the Company with respect to other members of the Board.

 

    -2-

     

    

 

(h)              
Company Policies. Except as otherwise explicitly provided herein, the parties to this Agreement acknowledge that
each of the New Directors, upon appointment to the Board, will be governed by the same protections and obligations regarding confidentiality
(including, for the avoidance of doubt, regulatory prohibitions on sharing or disclosing any confidential supervisory information
as provided by federal and state banking laws and regulations), conflicts of interest, related party transactions, fiduciary duties,
codes of conduct, trading and disclosure policies, director resignation policies and other governance guidelines and policies of
the Company as other directors on the Board (collectively, “Company Policies”), and shall have the same rights
and benefits, including with respect to insurance, indemnification, compensation, fees and reimbursement of expenses, as are applicable
to all non-employee directors of the Company.

 

2.                 
Cooperation.

 

(a)              
Cooperation Period. For purposes of this Agreement, the “Cooperation Period” shall mean the period
beginning on the date of this Agreement and ending on the one year anniversary of the date of this Agreement (the “Termination
Date”); provided, that:

 

(i)                
If, during the 30-day period preceding the expiration date of the period established pursuant to the Bylaws for the Company’s
stockholders to deliver valid notice of director nominations in connection with the 2022 Annual Meeting (the “Nomination
Date”), HoldCo nominates, or notifies the Company that it intends to nominate, any candidate for election to the Board,
then (A) the Cooperation Period shall earlier terminate on such Nomination Date and (B) HoldCo shall cause the Investor Nominee
contemporaneously to, and Investor Nominee shall, tender written notice to the Chair of the Board providing for his immediate resignation
from the Board and any committee of the Board on which he then sits; and

 

(ii)             
if the Cooperation Period does not terminate on the Nomination Date in accordance with clause (i) of this Section 2.1(a),
and the Board (in its sole discretion, subject to the consent of the Investor Nominee in accordance with Rule 14a-4(d)(4) under
the Exchange Act) nominates the Investor Nominee as a candidate for election to the Board in connection with the 2022 Annual Meeting,
then the Cooperation Period shall later terminate upon the first to occur of (A) the effective date of the Investor Nominee’s
resignation from the Board and (B) the date that is thirty (30) days prior to the expiration of the time period established pursuant
to the Bylaws for the Company’s stockholders to deliver notice of director nominations in connection with the Company’s
2023 Annual Meeting of Stockholders.

 

    -3-

     

    

 

(b)              
 Voting of HoldCo’s Shares. During the Cooperation Period, HoldCo will cause all the outstanding shares of
Company Common Stock that HoldCo has the right to vote as of the applicable record date, to be present in person (including by
means of remote communication) or by proxy for quorum purposes and to be voted at any meeting of stockholders of the Company, or
at any adjournments or postponements thereof, and to consent in connection with any action by written consent in lieu of a meeting:
(i) in favor of each director (including the New Directors) nominated and recommended by the Board for election at the 2021
Annual Meeting and, if applicable under the provisions of Section 2(a)(ii), the 2022 Annual Meeting; (ii) against any
proposals or resolutions to remove any member of the Board; and (iii) otherwise in accordance with the recommendation of the
Board on all other proposals or business that may be the subject of stockholder action at such meetings or written consents; provided,
however, that, if HoldCo is fully in compliance with this Agreement, HoldCo shall be permitted to vote in its sole discretion
on any proposal related to any Extraordinary Transaction (as defined below); provided, however, that in the event
that Institutional Shareholder Services or Glass Lewis & Co. (including any successor thereof) issues a voting recommendation
that differs from the voting recommendation of the Board with respect to any Company-sponsored proposal submitted to shareholders
at a shareholder meeting (other than with respect to the election of directors to the Board, the removal of directors from the
Board, the size of the Board and the filling of vacancies on the Board), then HoldCo shall be permitted to vote in accordance with
any such recommendation.

 

(c)              
Standstill. During the Cooperation Period or until such earlier time as the restrictions in this Section 2(c)
terminate as provided herein, HoldCo will not, and will cause its principals, directors, partners (including general partners),
officers, employees and agents and direct its other Representatives (collectively with HoldCo, “Restricted Persons”)
not to, directly or indirectly, without the prior written consent of the Board:

 

(i)                
acquire, or offer, seek or agree to acquire, by purchase or otherwise, or direct any third party in the acquisition of,
beneficial ownership of equity securities of the Company (or any securities convertible or exchangeable into or exercisable for
any such securities) or any assets of the Company, or rights or options to acquire any equity securities of the Company (or any
securities convertible or exchangeable into or exercisable for any such securities) or any assets of the Company, in each case,
that would result in HoldCo having (i) beneficial ownership of more than 9.9% or (ii) aggregate economic exposure of more than
14.9%, in each case, of the total number of outstanding shares of Company Common Stock as of the date of this Agreement;

 

(ii)             
(A) request or call for (publicly or otherwise, including, for the avoidance of doubt, public support for another person’s
request or call for) a special meeting of the Company’s stockholders (or the setting of a record date therefor), (B) seek,
alone or in concert with others, election or appointment to, or representation on, the Board, (C) nominate or propose the nomination
of, or recommend the nomination of, any candidate to the Board (including, for the avoidance of doubt, by making a change to the
size of the Board or proposing to fill any vacancies on the Board), (D) seek, alone or in concert with others, the removal
(including through any “withhold” or similar campaign) of any member of the Board, (E) make or be the proponent of
any stockholder proposal to the Company, or (F) conduct a referendum of stockholders; provided that nothing in this
Agreement will prevent HoldCo from identifying and nominating a Replacement Investor Nominee pursuant to Section 1(e);

 

    -4-

     

    

 

(iii)           
 engage in, directly or indirectly, any “solicitation” (as such term is used in the proxy rules of the SEC excluding,
for the avoidance of doubt, carve-outs relating to solicitations of ten or fewer stockholders) of proxies or consents, or advise,
encourage or influence any person with respect to the voting of any securities of the Company or any securities convertible or
exchangeable into or exercisable for any such securities, with respect to the election or removal of directors of the Company or
any other matter or proposal relating to the Company or become a “participant” (as such term is defined in Instruction
3 to Item 4 of Schedule 14A promulgated under the Exchange Act) in any such solicitation of proxies or consents;

 

(iv)            
make any public proposal with respect to (A) any waiver, amendment or modification to the Certificate or the Bylaws,
or other actions which may impede the acquisition of control of the Company by any person, (B) causing a class of securities
of the Company to be delisted from, or to cease to be authorized to be quoted on, any securities exchange or (C) causing a
class of securities of the Company to become eligible for termination of registration pursuant to Section 12(g)(4) of the
Exchange Act;

 

(v)              
form, join, participate in or act in concert with any “group” as defined in Section 13(d)(3) of the Exchange
Act, with respect to any securities of the Company (other than a “group” solely including other Restricted Persons
with respect to any securities of the Company now or hereafter owned by them);

 

(vi)            
encourage or advise any other person or knowingly assist any person in so encouraging or advising any person (A) with respect
to the giving or withholding of any proxy, consent or other authority to vote, any voting securities of the Company or (B) in conducting
any type of referendum relating to the Company (other than consistent with the Board’s recommendation in connection with
such matter, if applicable);

 

(vii)         
enter into a voting trust, arrangement or agreement, or subject any securities of the Company to any voting trust, arrangement
or agreement, in each case other than granting proxies in solicitations approved by the Board;

 

(viii)       
make or submit any proposal with respect to, or offer of (with or without conditions), or participate in any way in, either
alone or in concert with others, or encourage or support any tender offer, exchange offer, merger, amalgamation, consolidation,
acquisition, business combination, recapitalization, consolidation, restructuring, liquidation, dissolution or similar extraordinary
transaction involving the Company (including any of its subsidiaries or any of their respective securities or assets) (each, an
 “Extraordinary Transaction”), in each case, either publicly or in a manner that would reasonably require public
disclosure by the Company or HoldCo (it being understood that the foregoing will not restrict the Restricted Persons from tendering
shares, receiving payment for shares or otherwise participating in any Extraordinary Transaction initiated by a third party on
the same basis as other stockholders of the Company);

 

(ix)            
make any request for stock list materials or other books and records of the Company or any of its subsidiaries under Section
220 of the DGCL or other statutory or regulatory provisions providing for stockholder access to books and records;

 

    -5-

     

    

 

(x)              
 institute, solicit, or join, as a party, any litigation, arbitration or other proceeding against or involving the Company
or its current or former directors or officers (including derivative actions); provided, however, that, for the avoidance
of doubt, the foregoing shall not prevent any Restricted Person from (A) bringing litigation to enforce the provisions of
this Agreement instituted in accordance with and subject to Section 11, (B) making counterclaims with respect
to any proceeding initiated by, or on behalf of, the Company or its Affiliates against a Restricted Person, (C) bringing bona fide
commercial disputes that do not relate to the subject matter of this Agreement, (D) exercising statutory appraisal rights, or (E)
responding to or complying with a validly issued legal process;

 

(xi)            
enter into any negotiations, agreements (whether written or oral), arrangements or understandings with, or finance or intentionally
advise or facilitate, any third party to take any action that the Restricted Persons are prohibited from taking pursuant to this
Agreement;

 

(xii)         
make any public request or submit any proposal to amend or waive the terms of this Agreement (including this clause); or

 

(xiii)       
take any action that could reasonably be expected to cause or require the Company to make public disclosure with respect
to any of the foregoing;

 

    -6-

     

    

 

provided, that the restrictions
set forth in this Section 2(c) shall terminate automatically upon (i) ten (10) business days’ prior written
notice by HoldCo following a material breach of this Agreement by the Company (including a failure to nominate the New Directors
in accordance with Section 1) if such breach has not been cured within such notice period (provided that HoldCo
or the Investor Nominee is not in material breach of this Agreement at the time such notice is given or prior to the end of the
notice period); (ii) the Company’s entry into (x) a definitive agreement with respect to any Extraordinary Transaction
that would result in the acquisition by any person or group of more than 50% of the Company Common Stock or assets having an aggregate
value exceeding 50% of the aggregate enterprise value of the Company or (y) one or more definitive agreements providing for
a transaction or series of related transactions which would in the aggregate result in the Company issuing to one or more third
parties at least 20% of the Company Common Stock (including on an as-converted basis) outstanding immediately prior to such issuance(s)
(including in a PIPE, convertible note, convertible preferred security or similar structure) during the Cooperation Period (provided
that securities issued as consideration for (or in connection with) the acquisition of the assets, securities and/or business(es)
of another person by the Company or one or more of its subsidiaries shall not be counted toward this clause (y)); and (iii) the
commencement of any tender or exchange offer (by any person or group other than HoldCo) which, if consummated, would constitute
an Extraordinary Transaction that would result in the acquisition by any person or group of more than 50% of the Company Common
Stock, where the Company files with the SEC a Schedule 14D-9 (or amendment thereto) that does not recommend that its shareholders
reject such tender or exchange offer (it being understood that nothing herein will prevent the Company from issuing a “stop,
look and listen” communication pursuant to Rule 14d-9(f) promulgated under the Exchange Act in response to the commencement
of any tender or exchange offer); provided, that in the case of clauses (ii) and (iii), this Section 2(c) shall
terminate only (1) if the Investor Designee voted against the decision of the Board with respect to the relevant transaction and
(2) at such time the Investor Designee resigns from the Board and any committee of the Board on which he then sits. Notwithstanding
anything to the contrary in this Agreement, nothing in this Agreement (including but not limited to the restrictions in this Section
2(c)) will prohibit or restrict HoldCo from (A) making any public or private statement or announcement with respect to any
Extraordinary Transaction that is publicly announced by the Company or a Third Party, (B) making any factual statement to
comply with any subpoena or other legal process or respond to a request for information from any governmental authority with jurisdiction
over such person from whom information is sought, (C) granting any liens or encumbrances on any claims or interests in favor
of a bank or broker-dealer or prime broker holding such claims or interests in custody or prime brokerage in the ordinary course
of business, which lien or encumbrance is released upon the transfer of such claims or interests in accordance with the terms
of the custody or prime brokerage agreement(s), as applicable, (D) negotiating, evaluating and/or trading, directly or indirectly,
in any index fund, exchange traded fund, benchmark fund or broad basket of securities which may contain or otherwise reflect the
performance of, but not primarily consist of, securities of the Company or (E) providing its views privately to the Board
or management regarding any matter, or privately requesting a waiver of any provision of this Agreement, as long as such private
communications or requests would not reasonably be expected to require public disclosure of such communications or requests by
the Company or any of the Restricted Persons (it being understood that nothing in this clause (E) or otherwise obligates the Board
or management of the Company to any particular schedule or availability for communications with HoldCo or any Restricted Person
and no such communications or requests will unreasonably interfere with or impair the Board’s or management’s functioning
or impose unreasonable burdens on the Board or management).

 

(d)               Non-Disparagement.
Each of HoldCo and the Company agrees that, during the Cooperation Period, the Company and HoldCo shall refrain from making,
and shall cause the other Restricted Persons (including the Investor Nominee) not to make, any public statement or
announcement (including any statement or announcement that can reasonably be expected to become public), whether written or
oral, that constitutes an ad hominem attack on, or that otherwise disparages, defames, slanders, impugns or is reasonably
likely to damage the reputation of, (A) in the case of any such statements or announcements by any of HoldCo, the
Investor Nominee or the Restricted Persons, the Company and its Affiliates or any of its or their current or former
directors, officers or employees, and (B) in the case of any such statements or announcements by the Company or its
Affiliates, Associates and Representatives, HoldCo and their current or former principals, directors, members, general
partners, officers or employees, in each case, including (1) in any statement, document or report filed with, furnished
or otherwise provided to the SEC or any other governmental agency, (2) in any press release, podcast, Internet or social
media communication or other publicly available format, (3) to or through any beneficial owner of or potential investor in
any equity securities of the Company, or (4) to or through any journalist or member of the media (including in a
television, radio, newspaper, magazine or podcast interview, whether in print or on the Internet) or sell-side or buy-side
analyst (such statements or announcements, “Disparaging Statements”). The foregoing shall not
(x) restrict the ability of any person to comply with any subpoena or other legal process or respond to a request for
information from any governmental authority with jurisdiction over the party from whom information is sought or to enforce
such person’s rights hereunder or (y) apply to any private communications between and among HoldCo and the
Restricted Persons, on the one hand, and among the Company and its Affiliates and Representatives (in their capacity as
such), on the other hand. For the avoidance of doubt, nothing in this Section 2(d) shall (a) apply to private statements made
by HoldCo, its Affiliates or the Restricted Persons to any of their current or prospective clients, limited partners or
investors, or (b) prevent HoldCo or the Restricted Persons from referring to public statements made by HoldCo, prior to the
date of this Agreement, regarding the Company and the subject matter of this Agreement (subject to the provisions in Section
3), provided, that the overall context of the statements would not reasonably be viewed as disparaging or
defamatory.

 

    -7-

     

    

 

3.                 
Public Announcement. Unless otherwise agreed by the parties, not later than 9:00 a.m. Eastern Time on March 8, 2021,
the Company shall issue a press release in the form attached to this Agreement as Exhibit A (the “Press Release”).
Substantially concurrently with the release of the Press Release or otherwise by the applicable deadline for the SEC filings contemplated
by this sentence, the Company shall file a Current Report on Form 8-K disclosing the execution of this Agreement and attaching
the Press Release and this Agreement as exhibits. Neither HoldCo nor the Company or its Affiliates and Associates shall make any
public statement regarding the subject matter of this Agreement or the matters set forth in the Press Release prior to the issuance
of the Press Release.

 

4.                 
Confidentiality. The Company agrees that the Investor Nominee may provide to HoldCo confidential information of the
Company subject to, and solely in accordance with the terms of, a confidentiality agreement which HoldCo agrees to execute and
deliver to the Company simultaneously with HoldCo’s execution and delivery of this Agreement (the “Confidentiality
Agreement”). HoldCo agrees that any confidential or proprietary information of the Company that is subject to the Confidentiality
Agreement may not be used to make Disparaging Statements.

 

5.                 
Representations and Warranties of the Company. The Company represents and warrants to HoldCo as follows: (a) the
Company has the power and authority to execute, deliver and carry out the terms and provisions of this Agreement and to consummate
the transactions contemplated by this Agreement; (b) this Agreement has been duly and validly authorized, executed and delivered
by the Company, constitutes a valid and binding obligation and agreement of the Company and is enforceable against the Company
in accordance with its terms; and (c) the execution, delivery and performance of this Agreement by the Company does not and
will not (i) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to the Company, or (ii) result
in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute
a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination,
amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement
to which the Company is a party or by which it is bound. The Company acknowledges and agrees that neither HoldCo nor any of the
HoldCo Releasors has made, and the Company has not relied on, any express or implied representations or warranties with respect
to HoldCo or any Holdco Releasor not contained in Section 6.

 

    -8-

     

    

 

6.                  Representations
and Warranties of HoldCo. HoldCo represents and warrants to the Company as follows: (a) HoldCo has the power and
authority to execute, deliver and carry out the terms and provisions of this Agreement and to consummate the transactions
contemplated by this Agreement; (b) this Agreement has been duly and validly authorized, executed and delivered by
HoldCo, constitutes a valid and binding obligation and agreement of HoldCo and is enforceable against HoldCo in accordance
with its terms; (c) the execution, delivery and performance of this Agreement by HoldCo does not and will not
(i) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to HoldCo, or
(ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or
both could constitute a breach, violation or default) under or pursuant to, or result in the loss of a material benefit
under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement,
contract, commitment, understanding or arrangement to which HoldCo is a party or by which it is bound; (d) as of the
date of this Agreement, HoldCo beneficially owns 1,672,679 shares of Company Common Stock; (e) as of the date of this
Agreement, HoldCo does not own any debt securities of the Company. Upon the request of the Company, HoldCo will promptly
apprise the Company of its then-current beneficial ownership with respect to the shares of Company Common Stock so that the
Company may assess whether the ownership threshold set forth in Section 1(f) has been crossed; and (f) as of the date
of this Agreement, each of Michael Zaitzeff and Vikaran Ghei have withdrawn as a director nominee in connection with the 2021
annual meeting of stockholders of Boston Private Financial Holdings, Inc. HoldCo acknowledges and agrees that neither the
Company nor any of the Company Releasors has made, and HoldCo has not relied on, any express or implied representations or
warranties with respect to the Company or any Company Releasor not contained in Section 5.

 

7.                 
Release.

 

(a)              
Effective as of the date and time at which this Agreement is fully executed and delivered (the “Release Effective
Time”), (i) the Company, on its own behalf and on behalf of each other Company Releasor, releases and discharges HoldCo
or its current and former Representatives, and each of the successors and assigns of each of the foregoing, and (ii) HoldCo,
on its own behalf and on behalf of each other HoldCo Releasor, releases and discharges the Company, each of its Affiliates and
each of its and their respective current and former Representatives, and each of the successors and assigns of each of the foregoing,
in each case, from all Claims that such person has had or now has by reason of any cause or matter occurring prior to the Release
Effective Time directly or indirectly based upon, relating to, resulting from or arising out of the Company or ownership by HoldCo
of any securities of the Company, including any alleged or actual violations of federal or state securities laws or breach of fiduciary
duty claims under the DGCL or other applicable corporate law. The Company and HoldCo each represents that it has made no assignment
or transfer of any such Claims.

 

(b)              
Notwithstanding anything to the contrary in Section 7(a), nothing in this Agreement shall be deemed a release or
discharge of any obligation of any person to perform any of the terms, conditions and agreements contained in this Agreement, the
Confidentiality Agreement, that certain Non-Disclosure Agreement, dated as of February 22, 2021, by and between the Company and
HoldCo (the “Prior Confidentiality Agreement”) or any other agreement or document executed or delivered pursuant
to or in connection with this Agreement.

 

8.                 
Definitions. For purposes of this Agreement, the following terms have the following meanings:

 

(a)               
 “Affiliate” and “Associate” each have the meaning set forth in Rule 12b-2
promulgated by the SEC under the Exchange Act; provided, that none of the Company or its Affiliates or
Representatives, on the one hand, and HoldCo and its Affiliates or Representatives, on the other hand, shall be deemed to be
 “Affiliates” with respect to the other for purposes of this Agreement; provided, further, that
 “Affiliates” of a person shall not include any entity, solely by reason of the fact that one or more of such
person’s employees or principals serves as a member of its board of directors or similar governing body, unless such
person otherwise controls such entity (as the term “control” is defined in Rule 12b-2 promulgated by the SEC
under the Exchange Act);

 

    -9-

     

    

 

(b)              
 “beneficial ownership” and “beneficially own” have the respective meanings set forth
in Rule 13d-3 promulgated by the SEC under the Exchange Act, except that a person will also be deemed to be the beneficial
owner of all shares of the Company’s capital stock which such person has the right to acquire (whether such right is exercisable
immediately or only after the passage of time) pursuant to the exercise of any rights in connection with any securities or any
agreement, arrangement or understanding (whether or not in writing), regardless of when such rights may be exercised and whether
they are conditional, and all shares of the Company’s capital stock which such person or any of such person’s Affiliates
has or shares the right to vote or dispose;

 

(c)              
 “Claims” means all actions, rights, claims, proceedings, damages and liabilities of any kind or nature,
whether in law or equity, known or unknown;

 

(d)              
 “Company Releasor” means the Company, each of its Affiliates, each of its and their respective Representatives,
each of the successors and assigns of each of the foregoing, and any other person that may claim by, through or under any of them;

 

(e)              
“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

(f)               
 “HoldCo Releasor” means HoldCo, each of its Affiliates, each of its and their respective Representatives,
each of the successors and assigns of each of the foregoing, and any other person that may claim by, through or under any of them;

 

(g)              
 “person” or “persons” mean any individual, corporation (including not-for-profit),
general or limited partnership, limited liability or unlimited liability company, joint venture, estate, trust, association, organization
or other entity of any kind or nature;

 

(h)              
 “Qualified Director” means an individual who (i) qualifies as independent of the Company under
all applicable listing standards, applicable rules of the SEC and publicly disclosed standards used by the Board in determining
the independence of the Company’s directors, (ii) is not an employee, officer, director, principal, general partner,
manager or other agent of HoldCo or of any Affiliate of HoldCo, (iii) is not a limited partner, member or other investor in
HoldCo or any Affiliate or Associate of HoldCo, (iv) does not have any agreement, arrangement or understanding, written or
oral, with HoldCo or any Affiliate of HoldCo regarding such person’s service as a director on the Board and (v) meets
all other qualifications required for service as a director set forth in the Bylaws and the Company’s Corporate Governance
Policy;

 

(i)                
“Representative” means a party’s directors, members, partners (including general partners), managers,
principals, officers, employees, agents and other representatives; and

 

(j)                
 “SEC” means the U.S. Securities and Exchange Commission.

 

    -10-

     

    

 

9.                 
 Notices. All notices, consents, requests, instructions, approvals and other communications provided for in this
Agreement and all legal process in regard to this Agreement will be in writing and will be deemed validly given, made or served,
if (a) given by email, when such email is transmitted to the email address set forth below, and receipt of such email is acknowledged,
or (b) if given by any other means, when actually received during normal business hours at the address specified in this Section
9:

 

if to the Company:

Berkshire Hills Bancorp, Inc.

60 State Street

Boston, Massachusetts 02109

 

Attention:       Wm. Gordon Prescott

Executive Vice President and General
Counsel

Email:             GPrescott@berkshirebank.com

 

with a copy to:

Sullivan & Cromwell LLP

125 Broad Street

New York, New York 10004

Attention:      H. Rodgin Cohen, Mitchell S. Eitel

Email:            cohenhr@sullcrom.com, eitelm@sullcrom.com

 

if to HoldCo:

HoldCo Asset Management, LP

441 Lexington Avenue, 15th Floor

New York, New York 10017

Attention:      James E. McKee

General Counsel

Email:            james@holdcoam.com

 

with a copy to:

Olshan Frome Wolosky LLP

1325 Avenue of the Americas

New York, New York 10019

 

Attention:      Steve Wolosky,
Sebastian Alsheimer

Email:            SWolosky@olshanlaw.com, SAlsheimer@olshanlaw.com

 

    -11-

     

    

 

10.             
 Expenses. All fees, costs and expenses incurred in connection with this Agreement and all matters related to this
Agreement will be paid by the party incurring such fees, costs or expenses; provided, that the Company shall reimburse HoldCo
for its reasonable, documented out-of-pocket fees and expenses (including outside legal fees), not to exceed $75,000 in the aggregate,
incurred in connection with its nomination of director candidates for the 2021 Annual Meeting and the negotiation and execution
of this Agreement.

 

11.             
Specific Performance; Remedies; Governing Law; Venue.

 

(a)              
The Company and HoldCo acknowledge and agree that irreparable injury to the other party to this Agreement may occur in the
event any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached
and that such injury may not be adequately compensable by the remedies available at law (including the payment of money damages).
It is accordingly agreed that the Company and HoldCo will be entitled to injunction or injunctions or other equitable relief to
prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in addition to any other
remedy to which they are entitled at law or in equity. FURTHERMORE, THE COMPANY AND HOLDCO EACH AGREE (1) THE NON-BREACHING
PARTY WILL BE ENTITLED TO SEEK INJUNCTIVE AND OTHER EQUITABLE RELIEF, WITHOUT PROOF OF ACTUAL DAMAGES; (2) THE BREACHING PARTY
WILL NOT PLEAD IN DEFENSE THERETO THAT THERE WOULD BE AN ADEQUATE REMEDY AT LAW; AND (3) THE BREACHING PARTY AGREES TO WAIVE
ANY BONDING REQUIREMENT UNDER ANY APPLICABLE LAW, IN THE CASE ANY OTHER PARTY SEEKS TO ENFORCE THE TERMS BY WAY OF EQUITABLE RELIEF.

 

(b)              
This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. In addition, any
and all disputes, controversies, causes of action or claims arising out of or relating to this Agreement asserted by either party
(against the other), whether those claims sound in breach of contract, tort, fraud, or any other statutory or judicially created
cause of action and whether or not such claims are asserted in an arbitration, court of law or any other forum, will be governed
by and construed in accordance with the laws of the State of Delaware.

 

(c)              
The Company and HoldCo each (i) irrevocably and unconditionally submits to the personal jurisdiction of the Delaware
Court of Chancery (or, only if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, the federal
or other state courts located in Wilmington, Delaware), (ii) agrees that it will not attempt to deny or defeat such personal
jurisdiction by motion or other request for leave from any such courts, (iii) agrees that any actions or proceedings arising
in connection with this Agreement or the transactions contemplated by this Agreement shall be brought, tried and determined only
in such courts, (iv) waives any claim of improper venue or any claim that those courts are an inconvenient forum and (v) agrees
that it will not bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other
than the aforesaid courts. The parties to this Agreement agree that mailing of process or other papers in connection with any such
action or proceeding in the manner provided in Section 9 or in such other manner as may be permitted by applicable
law as sufficient service of process, shall be valid and sufficient service thereof.

 

    -12-

     

    

 

12.             
 Severability. If at any time subsequent to the date of this Agreement, any provision of this Agreement is held by
any court of competent jurisdiction to be illegal, void or unenforceable, such provision will be of no force and effect, but the
illegality or unenforceability of such provision will have no effect upon the legality or enforceability of any other provision
of this Agreement. Additionally, any such provision that is so held to be illegal, void or unenforceable shall be deemed deleted
from this Agreement to the minimum extent necessary and replaced by a provision that is valid and enforceable and that as closely
as practicable expresses the intention of such illegal, void or unenforceable provision.

 

13.             
Termination. This Agreement will terminate on the date that is the end date of the Cooperation Period. Upon such
termination, this Agreement shall have no further force and effect; provided, that (a) Sections 7 through 19 shall survive
termination of this Agreement; and (b) no termination of this Agreement shall relieve any party of liability for any breach of
this Agreement arising prior to such termination.

 

14.             
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an
original, but all of which shall constitute the same agreement and shall become a binding agreement when a counterpart has been
signed by each party and delivered to the other party. Signatures of the parties transmitted by facsimile, PDF or other electronic
file shall be deemed to be their original signatures for all purposes and the exchange of copies of this Agreement and of signature
pages by facsimile transmission, PDF or other electronic file shall constitute effective execution and delivery of this Agreement
as to the parties.

 

15.             
Affiliates. The Parties agree that they will cause their Affiliates, and their own and their Affiliates’ respective
Representatives, to comply with the terms of this Agreement.

 

16.             
No Third-Party Beneficiaries. This Agreement is solely for the benefit of the Company and HoldCo and is not enforceable
by any other persons. No party to this Agreement may assign its rights or delegate its obligations under this Agreement, whether
by operation of law or otherwise, without the prior written consent of the other parties, and any assignment in contravention of
this Section 16 will be null and void.

 

17.             
No Waiver. No failure or delay by any party in exercising any right or remedy hereunder will operate as a waiver
thereof, nor will any single or partial waiver thereof preclude any other or further exercise thereof or the exercise of any other
right or remedy hereunder.

 

18.             
Entire Understanding; Amendment. This Agreement and the Confidentiality Agreement contain the entire understanding
of the parties with respect to the subject matter of this Agreement and supersede any and all prior and contemporaneous agreements,
memoranda, arrangements and understandings, both written and oral, between the parties, or any of them, with respect to the subject
matter of this Agreement (including the Prior Confidentiality Agreement). This Agreement may be amended only by an agreement in
writing executed by the Company and HoldCo.

 

    -13-

     

    

 

19.              Interpretation
and Construction(a). The Company and HoldCo each acknowledge that it has been represented by counsel of its choice
throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the same with the
advice of said counsel. Each party and its counsel cooperated and participated in the drafting and preparation of this
Agreement and the documents referred to in this Agreement, and any and all drafts relating thereto exchanged among the
parties will be deemed the work product of all of the parties and may not be construed against any party by reason of its
drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any
ambiguities in this Agreement against any party that drafted or prepared it is of no application and is expressly waived by
the Company and HoldCo, and any controversy over interpretations of this Agreement will be decided without regard to events
of drafting or preparation. Whenever the words “include,” “includes” or “including” are
used in this Agreement, they shall be deemed to be followed by the words “without limitation.” For the avoidance
of doubt, any reference to a Representative of the Company or any of its Affiliates in this Agreement shall not be deemed to
be a reference to HoldCo or any of their Affiliates, and vice versa.

 

[Signature page follows]

 

    -14-

     

    

 

IN WITNESS WHEREOF, this Agreement has been
duly executed and delivered by the duly authorized signatories of the parties as of the date first written above.

 

 

	 	BERKSHIRE HILLS BANCORP, INC.
	 	 
	 	By:   	/s/ Wm. Gordon Prescott
	 	 	Name:	Wm. Gordon Prescott
	 	 	Title:	EVP and General Counsel

 

	 	HOLDCO ASSET MANAGEMENT, LP
	 	   
	 	By:   	/s/ James E. McKee
	 	 	Name:	James E. McKee
	 	 	Title:	General Counsel

 

[Signature Page
to Cooperation Agreement]

 

     

     

    

 

EXHIBIT A

Form of Press Release

 

[Attached.]

 

     

     

    

 

Berkshire Hills to Nominate Two New Directors
to the Company’s Board

 

Enters into Agreement with HoldCo Asset
Management

 

BOSTON, March 8, 2021 -- Berkshire Hills Bancorp, Inc. (NYSE:
BHLB) (“the Company”) today announced that it intends to nominate Michael (Misha) A. Zaitzeff and a second new independent
director selected by the Company with HoldCo’s consent, together with 11 current Directors, to stand for election to its
Board of Directors at the Company’s 2021 Annual Meeting of Shareholders, to be held on May 20, 2021. In connection with this
announcement, Berkshire has entered into a cooperation agreement with HoldCo Asset Management, LP ("HoldCo"), an
investment firm which owns approximately 3.3 percent of the Company’s outstanding shares. Mr. Zaitzeff is a co-founder and
managing member of VM II LLC, the general partner of HoldCo Asset Management, LP.

 

“We are pleased to have reached this agreement with HoldCo
and look forward to welcoming Misha to our Board,” said J. Williar Dunlaevy, Chairman of the Board of the Company. “This
agreement underscores our commitment to listening to and incorporating the views of our investors in our purpose-driven mission
to enhance value for all stakeholders, including our shareholders, customers, employees and the communities we serve. We believe
that Misha will bring a valuable perspective as we continue to work with our new CEO, Nitin Mhatre, in further developing our strategic
plan for the future of Berkshire.”

 

“We appreciate the constructive dialogue we have had with
Berkshire throughout this process and believe that today’s agreement is an important step in improving the Company’s
performance and strengthening shareholder alignment for the benefit of all shareholders,” Mr. Zaitzeff commented. “I
look forward to bringing the perspective of a large shareholder to the Board as Nitin and his management team continue to develop
their plan to enhance value at Berkshire.”

 

Pursuant to the agreement, HoldCo will vote all of its shares
in favor of each of the Company’s nominees at the 2021 Annual Meeting and has agreed to certain customary standstill provisions
and other voting commitments. The complete agreement between the Company and HoldCo will be filed by the Company on Form 8-K with
the United States Securities and Exchange Commission.

 

The Company’s Board of Directors will present its complete
slate of director nominees for the 2021 Annual Meeting in the Company’s proxy statement and other materials to be filed with
the Securities and Exchange Commission and furnished to all shareholders eligible to vote at the 2021 Annual Meeting of Shareholders.

 

J.P. Morgan is serving as financial advisor and Sullivan &
Cromwell LLP is serving as legal counsel to Berkshire.

 

     

     

    

 

About Michael (Misha) A. Zaitzeff 

 

Misha Zaitzeff is a co-founder and managing member of VM
GP II LLC, the general partner of HoldCo Asset Management, LP. Mr. Zaitzeff has served as a member of numerous corporate
boards, oversight committees and creditor committees. Mr. Zaitzeff served on the Trust Advisory Board of WMI Liquidating
Trust, a trust created to implement the Chapter 11 Bankruptcy Plan of Washington Mutual, Inc. Mr. Zaitzeff holds a Bachelor
of Arts in Computer Science from Brown University.

 

About Berkshire Hills Bancorp

 

Berkshire Hills Bancorp is the parent of Berkshire Bank, a 21st
century community bank pursuing purpose driven performance based on its Be FIRST corporate responsibility culture. Headquartered
in Boston, Berkshire operates 124 banking offices in seven Northeastern states, with approximately $12.8 billion in assets.

 

About HoldCo Asset Management

 

HoldCo Asset Management, LP (“HoldCo”) is an investment
adviser located in New York City. HoldCo was founded by Vik Ghei and Misha Zaitzeff. HoldCo currently has over $1 billion in regulatory
assets under management. HoldCo manages private investment funds using a value-based philosophy with a fundamental bottoms-up approach
to analyzing each investment. HoldCo’s flagship funds have broad mandates to invest in public and private markets across
corporate credit, structured credit, real estate and equity securities.

 

Forward-Looking Statements

 

This document contains "forward-looking statements"
within the meaning of section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of
1934, as amended. You can identify these statements from the use of the words "may," "will," "should,"
 "could," "would," "plan," "potential," "estimate," "project," "believe,"
 "intend," "anticipate," "expect," "target" and similar expressions. There are many factors
that could cause actual results to differ significantly from expectations described in the forward-looking statements. For a discussion
of such factors, please see Berkshire's most recent reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission
(the “SEC”) and available on the SEC's website at www.sec.gov.

 

Further, given its ongoing and dynamic nature, it is difficult
to predict what continued effects the novel coronavirus (COVID-19) pandemic will have on our business and results of operations.
The pandemic and the related local and national economic disruption may result in a continued decline in demand for our products
and services; increased levels of loan delinquencies, problem assets and foreclosures; an increase in our allowance for loan losses;
a decline in the value of loan collateral, including real estate; a greater decline in the yield on our interest-earning assets
than the decline in the cost of our interest-bearing liabilities; and increased cybersecurity risks, as employees increasingly
work remotely.

 

Accordingly, you should not place undue reliance on forward-looking
statements, which reflect our expectations only as of the date of this document. Berkshire does not undertake any obligation to
update forward-looking statements.

 

Information in this press release regarding HoldCo has been
provided to the Company by HoldCo.

 

     

     

    

 

Important Information

 

The Company plans to file with the SEC and furnish to its stockholders
a proxy statement in connection with its 2021 Annual Meeting of Shareholders. The Company advises its shareholders to read the
proxy statement when it becomes available, because it will contain important information. Shareholders may obtain a free copy of
the proxy statement and other documents filed with the SEC on the SEC’s website, www.sec.gov, or by directing a request to
Berkshire Hills Bancorp, Inc., Attention: Executive Vice President, General Counsel and Corporate Secretary, 60 State Street, Boston,
Massachusetts 02109. The Company and its directors and executive officers may be deemed to be participants in the solicitation
of proxies from the Company’s shareholders in connection with the 2021 Annual Meeting. Shareholders may obtain information
regarding such individuals on the Company’s website, https://ir.berkshirebank.com, and in the Company’s proxy statement
filed with the SEC on April 4, 2020 in connection with the Company’s 2020 Annual Meeting of Shareholders. To the extent holdings
of the Company’s securities by its directors and executive officers have changed since the amounts included in the 2020 proxy
statement, such changes have been reflected on Statements of Changes of Beneficial Ownership on Form 4 filed with the SEC.

 

Berkshire Hills Bancorp Investor Relations Contacts:

 

David Gonci, Capital Markets Director

dgonci@berkshirebank.com

(413) 281-1973

 

Berkshire Hills Bancorp Media Contacts:

 

Steve Frankel / Ed Trissel / Andrew Squire

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449

 

HoldCo Asset Management Contacts:

 

Dan Zacchei / Joe Germani

Sloane & Company

dzacchei@sloanepr.com / jgermani@sloanepr.com

 

James McKee

james@holdcoam.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]